Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.
about
TPO-RAs in pITP: description of a case series and analysis of predictive factors for response.Emerging drugs for immune thrombocytopenia (ITP).Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case.Remissions after long-term use of romiplostim for immune thrombocytopeniaInnovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future.
P2860
Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Feasibility of romiplostim dis ...... n real life clinical practice.
@ast
Feasibility of romiplostim dis ...... n real life clinical practice.
@en
type
label
Feasibility of romiplostim dis ...... n real life clinical practice.
@ast
Feasibility of romiplostim dis ...... n real life clinical practice.
@en
prefLabel
Feasibility of romiplostim dis ...... n real life clinical practice.
@ast
Feasibility of romiplostim dis ...... n real life clinical practice.
@en
P2093
P2860
P356
P1433
P1476
Feasibility of romiplostim dis ...... n real life clinical practice.
@en
P2093
Enrica Morra
Enrico Maria Pogliani
Marilena Fedele
Monica Carpenedo
Silvia Cantoni
Veronica Coccini
P2860
P356
10.4081/HR.2015.5673
P577
2015-02-24T00:00:00Z